Home > Publications Database > The Role of Atrial Fibrillation and Oral Anticoagulation Status in Health-Related Quality of Life 12 Months After Ischemic Stroke or TIA. > print

001     275876
005     20250126000507.0
024 7 _ |a 10.1002/brb3.70248
|2 doi
024 7 _ |a pmid:39779216
|2 pmid
024 7 _ |a pmc:PMC11710889
|2 pmc
024 7 _ |a altmetric:172896152
|2 altmetric
037 _ _ |a DZNE-2025-00111
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Olma, Manuel C
|0 0000-0001-8153-3025
|b 0
245 _ _ |a The Role of Atrial Fibrillation and Oral Anticoagulation Status in Health-Related Quality of Life 12 Months After Ischemic Stroke or TIA.
260 _ _ |a Malden, Mass.
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1737365399_4997
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Atrial fibrillation (AF) accounts for about 20% of all ischemic strokes worldwide. It is known that AF impairs health-related quality of life (HRQOL) in the general population, but data on HRQOL in stroke patients with newly diagnosed AF are sparse.Post hoc analysis of the prospective, investigator-initiated, multicenter MonDAFIS study (NCT02204267) to analyze whether AF-related oral anticoagulation (OAC), and/or AF-symptom severity are associated with HRQOL after ischemic stroke or transient ischemic attack (TIA). HRQOL was measured using the EQ-5D-3L-questionnaire (including EQ-index/EQ-VAS) at baseline and after 12 months using multivariable linear mixed models. AF symptom severity was assessed using the European Heart Rhythm Association classification and symptom severity score (EHRA score) categorizing patients with no/mild/severe/disabling AF-related symptoms.A first episode of AF was detected in 261/2927 (8.9%) patients within 12 months after the index stroke and 227/2920 (7.8%) patients had AF and were anticoagulated at 12 months. HRQOL (measured by EQ-index, n = 2495 patients) was higher in AF patients on OAC compared to AF patients without OAC at 12 months after stroke (mean difference: MD: -16.8, 95% CI: 5.6 to 28.0), and similar in AF patients under OAC compared with patients without AF (MD: 2.0, 95% CI: -2.2 to 6.3). AF-related symptoms were negatively associated with HRQOL (measured by EQ-index) indicating that stroke patients with AF-related symptoms had a lower HRQOL compared to asymptomatic AF patients (mild vs. asymptomatic: MD: -9.0, 95% CI: -17.7 to -0.3; severe/disabling vs. asymptomatic: MD: -19.1, 95% CI: -34.7 to -3.4).Stroke patients with newly diagnosed AF are at risk of lower quality of life at 12 months, depending on OAC status and AF symptom severity.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a atrial fibrillation
|2 Other
650 _ 7 |a ischemic stroke
|2 Other
650 _ 7 |a oral anticoagulation
|2 Other
650 _ 7 |a quality of life
|2 Other
650 _ 7 |a transient ischemic attack
|2 Other
650 _ 7 |a Anticoagulants
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Atrial Fibrillation: drug therapy
|2 MeSH
650 _ 2 |a Atrial Fibrillation: physiopathology
|2 MeSH
650 _ 2 |a Atrial Fibrillation: complications
|2 MeSH
650 _ 2 |a Quality of Life
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Anticoagulants: administration & dosage
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Ischemic Stroke: physiopathology
|2 MeSH
650 _ 2 |a Ischemic Attack, Transient: physiopathology
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Administration, Oral
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
700 1 _ |a Steindorf-Sabath, Lena
|b 1
700 1 _ |a Tütüncü, Serdar
|0 0000-0002-5057-7487
|b 2
700 1 _ |a Kunze, Claudia
|b 3
700 1 _ |a Fiessler, Cornelia
|b 4
700 1 _ |a Kirchhof, Paulus
|b 5
700 1 _ |a Dietzel, Joanna
|b 6
700 1 _ |a Schurig, Johannes
|b 7
700 1 _ |a Oschmann, Patrick
|b 8
700 1 _ |a Niehaus, Ludwig
|b 9
700 1 _ |a Urbanek, Christian
|b 10
700 1 _ |a Thomalla, Götz
|b 11
700 1 _ |a Nabavi, Darius G
|b 12
700 1 _ |a Röther, Joachim
|b 13
700 1 _ |a Laufs, Ulrich
|b 14
700 1 _ |a Veltkamp, Roland
|b 15
700 1 _ |a Heuschmann, Peter U
|b 16
700 1 _ |a Haeusler, Karl Georg
|b 17
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 18
|e Last author
|u dzne
700 1 _ |a Investigators, MonDAFIS
|b 19
|e Collaboration Author
773 _ _ |a 10.1002/brb3.70248
|g Vol. 15, no. 1, p. e70248
|0 PERI:(DE-600)2623587-0
|n 1
|p e70248
|t Brain and behavior
|v 15
|y 2025
|x 2162-3279
856 4 _ |u https://pub.dzne.de/record/275876/files/DZNE-2025-00111%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/275876/files/DZNE-2025-00111.pdf
856 4 _ |u https://pub.dzne.de/record/275876/files/DZNE-2025-00111%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/275876/files/DZNE-2025-00111%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/275876/files/DZNE-2025-00111%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/275876/files/DZNE-2025-00111.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:275876
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2811033
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN BEHAV : 2022
|d 2024-12-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-06
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:05:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:05:29Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-06
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-06
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-06
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-06
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1811005
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21